Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BARD1 Double Nickase Plasmid (h): sc-401212-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BARD1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BARD1 Double Nickase Plasmid (h) and BARD1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting BARD1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BARD1 Antibody (E-11): sc-74559
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BARD1 Double Nickase Plasmid (h) | sc-401212-NIC | 20 µg | $410.00 | |||
BARD1 Double Nickase Plasmid (h2) | sc-401212-NIC-2 | 20 µg | $410.00 |
BARD1 (BRCA1 associated RING domain 1) is a tumor suppressor protein that forms an obligate heterodimer with BRCA1 to create an E3 ubiquitin ligase complex central to genome stability. This complex coordinates DNA double-strand break repair, replication fork protection, and cell-cycle checkpoint signaling, linking BARD1 to homologous recombination and broader DNA damage response pathways. Through its RING and ankyrin repeat domains, BARD1 helps regulate protein ubiquitination and the recruitment of repair factors at sites of damage. Dysregulation or pathogenic variants in BARD1 have been associated with impaired DNA repair capacity and increased genomic instability, supporting its relevance in studies of cancer susceptibility mechanisms.
BARD1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the BARD1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within BARD1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt BARD1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of BARD1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.